Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 trial of aderbasib for breast cancer.

Next Previous
X
Search
Trial Profile

A phase 2 trial of aderbasib for breast cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2016

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aderbasib (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 11 Feb 2016 Based on the interim results of JANUS 1 and the phase 2 sub-study in patients with metastatic colorectal cancer and CRP, ongoing Incyte-sponsored trials of ruxolitinib in solid tumors will be discontinued, including the phase 3 JANUS 2 study in pancreatic cancer, the Phase 2 sub-study in patients with metastatic colorectal cancer and low CRP, and the phase 2 studies in breast and lung cancer, according to an Incyte Corporation media release.
    • 02 Nov 2007 Status changed from planning to recruiting.
    • 02 Oct 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top